Allergan

From Wikipedia, the free encyclopedia - View original article

Allergan, Inc.
TypePublic
Traded as
IndustryPharmaceuticals
Founded1948
HeadquartersIrvine, California
Key people
ProductsBotox, Acular, Acuvail, Alocril, Prevage, Avage, Tazorac, Juvederm, Lap-band, Restasis, Alphagan, Ganfort, Hydrafill, Optive
RevenueIncrease US$5.8 Billion (2012)[1]:F-5
Operating incomeIncrease US$1.6 Billion (2012)[1]:F-5
Net incomeIncrease US$1.1 Billion (2012)[1]:F-6
Total assetsIncrease US$9.2 Billion (2012)[1]:F-4
Total equityIncrease US$5.9 Billion (2012)[1]:F-4
Employees10,800[1]:20 (~2,000 in R&D)[1]:8 (2012)
Websiteallergan.com
 
Jump to: navigation, search
Allergan, Inc.
TypePublic
Traded as
IndustryPharmaceuticals
Founded1948
HeadquartersIrvine, California
Key people
ProductsBotox, Acular, Acuvail, Alocril, Prevage, Avage, Tazorac, Juvederm, Lap-band, Restasis, Alphagan, Ganfort, Hydrafill, Optive
RevenueIncrease US$5.8 Billion (2012)[1]:F-5
Operating incomeIncrease US$1.6 Billion (2012)[1]:F-5
Net incomeIncrease US$1.1 Billion (2012)[1]:F-6
Total assetsIncrease US$9.2 Billion (2012)[1]:F-4
Total equityIncrease US$5.9 Billion (2012)[1]:F-4
Employees10,800[1]:20 (~2,000 in R&D)[1]:8 (2012)
Websiteallergan.com
Allergan headquarters in Irvine

Allergan, Inc., is a global pharmaceutical company, focusing on ophthalmic pharmaceuticals, dermatology, neuroscience, urology and cosmetics.[2]

Profile[edit]

The company produces a neurologic product, Botox, which is used to treat debilitating disorders associated with muscle overactivity. The company owns the trade names Botox Cosmetic and Vistabel — for the treatment of facial lines.

The company manufacturing plants are in Waco, Texas; Westport, Ireland; San Jose, Costa Rica and Bridgewater, New Jersey (opened in 2012).[2]

On April 23, 2001, the company participated in the annual meeting of the European Bank for Reconstruction and Development (London to Tues).[3]

The company is a member of the American Legislative Exchange Council (ALEC).[4] The company is the state corporate co-chair of Tennessee, a "Chairman" level sponsor of 2011 ALEC Annual Conference, and a member of Louisiana Host Committee.[5]

Corporate affairs[edit]

Acquisition[edit]

On March 1st, 2013, the company acquired MAP Pharmaceuticals Inc., which is a development-stage company mainly researching the treatment of migraine and other oral drugs in Neurology. The principal products of this sub-company are under review with the US Food and Drug Administration (FDA). [6]

Safety reports[edit]

In 2011, FDA reported issues in the investigation of safety of silicone gel-filled breast implants. However, the company announced later the reassurance to patients of the safety and exclusion of its drugs from the investigated breast implant devices, stating that all of its products are above safety standards around the world.[7]

In December 2013, the company sold its obesity intervention business to Apollo Endosurgery, Inc., for a cash payment of $75 million and a $15 million minority equity interest in Apollo Endosurgery.[8]

Products[edit]


Notes[edit]

  1. ^ a b c d e f g "Annual Report". Form 10-K. Allergan. 2012. Retrieved January 5, 2014. 
  2. ^ a b Bhutta, Sunya (December 2013). "Biopharma Blossoming in the Garden State" (paper). Gen. Eng. Biotechnol. News 33 (21). p. 15.  open access publication - free to read
  3. ^ "This Week". (registration required)
  4. ^ "ALEC Corporations". SourceWatch. September 2013. Archived from the original on January 5, 2014. Retrieved January 5, 2014. 
  5. ^ "ALEC State Chairmen". SourceWatch. December 2, 2013. Tennessee. Archived from the original on January 5, 2014. Retrieved January 5, 2014. 
  6. ^ https://www.google.com/finance?cid=630
  7. ^ http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=635213
  8. ^ "Allergan, Inc. Completes Sale of Obesity Intervention Business". 

External links[edit]